DNA damage response and repair: insights into strategies for radiation sensitization of gliomas.
暂无分享,去创建一个
Joshua D. Lawson | S. Kesari | B. Carter | K. Kahle | S. Advani | Clark C. Chen | K. Ng
[1] Susan Meyer Goldstein,et al. Ten years after: Interference of hospital slack in process performance benefits of quality practices , 2012 .
[2] M. Labussière,et al. Radiosensitizing properties of bortezomib depend on therapeutic schedule. , 2011, International journal of radiation oncology, biology, physics.
[3] D. Hochhauser,et al. EGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatment. , 2011, Cancer research.
[4] R. Bristow,et al. Poly(ADP-ribose) polymerase inhibition as a model for synthetic lethality in developing radiation oncology targets. , 2010, Seminars in radiation oncology.
[5] L. Chin,et al. Targeting EGFR Induced Oxidative Stress by PARP1 Inhibition in Glioblastoma Therapy , 2010, PloS one.
[6] Jiandong Chen,et al. Mechanism of p53 stabilization by ATM after DNA damage , 2010, Cell cycle.
[7] N. Mailand,et al. HERC2 coordinates ubiquitin-dependent assembly of DNA repair factors on damaged chromosomes , 2010, Nature Cell Biology.
[8] S. Toms,et al. Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme , 2010, Journal of Neuro-Oncology.
[9] J. Bartek,et al. The DNA-damage response in human biology and disease , 2009, Nature.
[10] Ralph Scully,et al. Mechanisms of double-strand break repair in somatic mammalian cells. , 2009, The Biochemical journal.
[11] J. Lam-mcculloch,et al. Saddle block analgesia for high-dose-rate brachytherapy: A prospective study. , 2009, Brachytherapy.
[12] J. Parvin,et al. Cdk1 participates in BRCA1-dependent S phase checkpoint control in response to DNA damage. , 2009, Molecular cell.
[13] D. Ferguson,et al. Multiple functions of MRN in end-joining pathways during isotype class switching , 2009, Nature Structural &Molecular Biology.
[14] W. Curran,et al. Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignancies. , 2009, International journal of radiation oncology, biology, physics.
[15] Bruce Mickey,et al. EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma. , 2009, Cancer research.
[16] R. Mirimanoff,et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.
[17] Ji Luo,et al. Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction , 2009, Cell.
[18] J. Ellenberg,et al. RNF168 Binds and Amplifies Ubiquitin Conjugates on Damaged Chromosomes to Allow Accumulation of Repair Proteins , 2009, Cell.
[19] Susan M. Chang,et al. Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] K. Camphausen,et al. In vitro and In vivo Radiosensitization of Glioblastoma Cells by the Poly (ADP-Ribose) Polymerase Inhibitor E7016 , 2009, Clinical Cancer Research.
[21] A. D’Andrea,et al. Of Escherichia coli and Man: Understanding Glioma Resistance to Temozolomide Therapy , 2009 .
[22] S. Kesari,et al. A small interference RNA screen revealed proteasome inhibition as strategy for glioblastoma therapy. , 2009, Clinical neurosurgery.
[23] Caterina Giannini,et al. Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] A. Chalmers,et al. Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-Ribose) polymerase: mechanisms and therapeutic potential. , 2008, International journal of radiation oncology, biology, physics.
[25] Hong Wang,et al. Erlotinib attenuates homologous recombinational repair of chromosomal breaks in human breast cancer cells. , 2008, Cancer research.
[26] D. Busam,et al. An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.
[27] Joshua M. Korn,et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.
[28] A. Robles,et al. HSP90 inhibitor, DMAG, synergizes with radiation of lung cancer cells by interfering with base excision and ATM-mediated DNA repair , 2008, Molecular Cancer Therapeutics.
[29] S. Jackson,et al. Phospho-dependent interactions between NBS1 and MDC1 mediate chromatin retention of the MRN complex at sites of DNA damage , 2008, EMBO reports.
[30] K. Camphausen,et al. In vitro and In vivo Radiosensitization Induced by the DNA Methylating Agent Temozolomide , 2008, Clinical Cancer Research.
[31] M. Ljungman,et al. Phenylbutyrate interferes with the Fanconi anemia and BRCA pathway and sensitizes head and neck cancer cells to cisplatin , 2008, Molecular Cancer.
[32] J Wade Harper,et al. The DNA damage response: ten years after. , 2007, Molecular cell.
[33] Michael B. Yaffe,et al. RNF8 Transduces the DNA-Damage Signal via Histone Ubiquitylation and Checkpoint Protein Assembly , 2007, Cell.
[34] Jiri Bartek,et al. Human CtIP promotes DNA end resection , 2007, Nature.
[35] M. Mehta,et al. Radiotherapy and radiosensitizers in the treatment of glioblastoma multiforme. , 2007, Clinical advances in hematology & oncology : H&O.
[36] H. Kimura,et al. Inhibitors of the proteasome suppress homologous DNA recombination in mammalian cells. , 2007, Cancer research.
[37] K. Camphausen,et al. Inhibition of Hsp90: A Multitarget Approach to Radiosensitization , 2007, Clinical Cancer Research.
[38] Junjie Chen,et al. Ubiquitin-Binding Protein RAP80 Mediates BRCA1-Dependent DNA Damage Response , 2007, Science.
[39] Luc Taillandier,et al. Radiotherapy for glioblastoma in the elderly. , 2007, The New England journal of medicine.
[40] P. Dent,et al. Extracellular signal-related kinase positively regulates ataxia telangiectasia mutated, homologous recombination repair, and the DNA damage response. , 2007, Cancer research.
[41] R. Kanaar,et al. DNA double-strand break repair: all's well that ends well. , 2006, Annual review of genetics.
[42] K. Camphausen,et al. Inhibition of hsp90 compromises the DNA damage response to radiation. , 2006, Cancer research.
[43] K. Aldape,et al. Temozolomide-Mediated Radiation Enhancement in Glioblastoma: A Report on Underlying Mechanisms , 2006, Clinical Cancer Research.
[44] D. Wazer,et al. DSS1 is required for the stability of BRCA2 , 2006, Oncogene.
[45] David N Louis,et al. Molecular pathology of malignant gliomas. , 2006, Annual review of pathology.
[46] F. Alt,et al. MDC1 maintains genomic stability by participating in the amplification of ATM-dependent DNA damage signals. , 2006, Molecular cell.
[47] M. Yaffe,et al. MDC1 Directly Binds Phosphorylated Histone H2AX to Regulate Cellular Responses to DNA Double-Strand Breaks , 2005, Cell.
[48] Koji Yoshimoto,et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. , 2005, The New England journal of medicine.
[49] V. Macaulay,et al. EGFR Mutations and Lung Cancer , 2005, PLoS Medicine.
[50] Haico van Attikum,et al. The histone code at DNA breaks: a guide to repair? , 2005, Nature Reviews Molecular Cell Biology.
[51] David J. Chen,et al. Radiation-induced Epidermal Growth Factor Receptor Nuclear Import Is Linked to Activation of DNA-dependent Protein Kinase* , 2005, Journal of Biological Chemistry.
[52] S. West,et al. BRCA2 BRC motifs bind RAD51-DNA filaments. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[53] Sheng-Chieh Hsu,et al. Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. , 2005, Cancer cell.
[54] Ji-Hoon Lee,et al. ATM Activation by DNA Double-Strand Breaks Through the Mre11-Rad50-Nbs1 Complex , 2005, Science.
[55] T. Paull,et al. The Mre11/Rad50/Nbs1 Complex and Its Role as a DNA Double-Strand Break Sensor for ATM , 2005, Cell cycle.
[56] Martin J. van den Bent,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[57] P. Richardson,et al. Proteasome inhibition as a novel therapeutic target in human cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[58] G. Cagney,et al. Proteasome involvement in the repair of DNA double-strand breaks. , 2004, Molecular cell.
[59] A. Ashworth,et al. DSS1 is required for RAD51 focus formation and genomic stability in mammalian cells , 2004, EMBO reports.
[60] A. Venkitaraman,et al. DNA recombination, chromosomal stability and carcinogenesis: insights into the role of BRCA2. , 2004, DNA repair.
[61] J. Tainer,et al. Structure and function of the double-strand break repair machinery. , 2004, DNA repair.
[62] S. Ferrari,et al. Mismatch repair-dependent G2 checkpoint induced by low doses of SN1 type methylating agents requires the ATR kinase. , 2004, Genes & development.
[63] S. West,et al. RAD51C Is Required for Holliday Junction Processing in Mammalian Cells , 2004, Science.
[64] R. Kanaar,et al. Rad52 and Ku bind to different DNA structures produced early in double-strand break repair. , 2003, Nucleic acids research.
[65] Yunmei Ma,et al. Mechanism and regulation of human non-homologous DNA end-joining , 2003, Nature Reviews Molecular Cell Biology.
[66] S. Powell,et al. Roles of BRCA1 and BRCA2 in homologous recombination, DNA replication fidelity and the cellular response to ionizing radiation , 2003, Oncogene.
[67] M. Kastan,et al. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation , 2003, Nature.
[68] Wen-Hwa Lee,et al. BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure. , 2002, Science.
[69] T. Mak,et al. Chk2 regulates irradiation-induced, p53-mediated apoptosis in Drosophila , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[70] S. Jackson,et al. The MRE11 complex: at the crossroads of DNA repair and checkpoint signalling , 2002, Nature Reviews Molecular Cell Biology.
[71] R. Abraham. Cell cycle checkpoint signaling through the ATM and ATR kinases. , 2001, Genes & development.
[72] J. Walker,et al. Structure of the Ku heterodimer bound to DNA and its implications for double-strand break repair , 2001, Nature.
[73] S. Elledge,et al. Direct DNA binding by Brca1 , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[74] J. Turchi,et al. Cisplatin-DNA adducts inhibit translocation of the Ku subunits of DNA-PK. , 2000, Nucleic acids research.
[75] V. Yamazaki,et al. A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage , 2000, Current Biology.
[76] D. Ramsden,et al. Ku Recruits the XRCC4-Ligase IV Complex to DNA Ends , 2000, Molecular and Cellular Biology.
[77] J. Harper,et al. Anticancer drug targets: cell cycle and checkpoint control. , 1999, The Journal of clinical investigation.
[78] S. Jackson,et al. DNA double-strand break repair , 1999, Current Biology.
[79] K. Kinzler,et al. 14-3-3σ is required to prevent mitotic catastrophe after DNA damage , 1999, Nature.
[80] M. Eijpe,et al. Mre11 and Ku70 interact in somatic cells, but are differentially expressed in early meiosis , 1999, Nature Genetics.
[81] E. Rogakou,et al. Megabase Chromatin Domains Involved in DNA Double-Strand Breaks in Vivo , 1999, The Journal of cell biology.
[82] A. Ashworth,et al. Interaction between the Product of the Breast Cancer Susceptibility Gene BRCA2 and DSS1, a Protein Functionally Conserved from Yeast to Mammals , 1999, Molecular and Cellular Biology.
[83] V. Ferrans,et al. Ras Proteins Induce Senescence by Altering the Intracellular Levels of Reactive Oxygen Species* , 1999, The Journal of Biological Chemistry.
[84] K. Kinzler,et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. , 1998, Science.
[85] Y. Yamaguchi-Iwai,et al. Homologous recombination and non‐homologous end‐joining pathways of DNA double‐strand break repair have overlapping roles in the maintenance of chromosomal integrity in vertebrate cells , 1998, The EMBO journal.
[86] J. Haber,et al. Saccharomyces Ku70, Mre11/Rad50, and RPA Proteins Regulate Adaptation to G2/M Arrest after DNA Damage , 1998, Cell.
[87] T. Lindahl,et al. A newly identified DNA ligase of Saccharomyces cerevisiae involved in RAD52-independent repair of DNA double-strand breaks. , 1997, Genes & development.
[88] M. Resnick,et al. A double-strand break within a yeast artificial chromosome (YAC) containing human DNA can result in YAC loss, deletion or cell lethality , 1996, Molecular and cellular biology.
[89] Julian Peto,et al. Identification of the breast cancer susceptibility gene BRCA2 , 1996, Nature.
[90] D. Bentley,et al. Identification of the breast cancer susceptibility gene BRCA2 , 1995, Nature.
[91] K. Kinzler,et al. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. , 1995, Cancer research.
[92] M. Skolnick,et al. BRCA1 mutations in primary breast and ovarian carcinomas. , 1994, Science.
[93] Steven E. Bayer,et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.
[94] A. Giaccia,et al. The human Ha-ras oncogene induces genomic instability in murine fibroblasts within one cell cycle. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[95] Virginia A. Zakian,et al. Loss of a yeast telomere: Arrest, recovery, and chromosome loss , 1993, Cell.
[96] M. Resnick,et al. Lethality induced by a single site-specific double-strand break in a dispensable yeast plasmid. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[97] S. Jackson,et al. The DNA-dependent protein kinase: Requirement for DNA ends and association with Ku antigen , 1993, Cell.
[98] N. Bleehen,et al. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party. , 1991, British Journal of Cancer.
[99] D P Byar,et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. , 1980, The New England journal of medicine.
[100] M. Walker,et al. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. , 1979, International journal of radiation oncology, biology, physics.
[101] J. Hendry,et al. Radiobiology for the Radiologist , 1979, British Journal of Cancer.
[102] E. Alexander,et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. , 1978, Journal of neurosurgery.
[103] E. Gehan,et al. Evaluation of mithramycin in the treatment of anaplastic gliomas. , 1976, Journal of neurosurgery.
[104] C. J. Gillespie,et al. DNA strand breaks, repair, and survival in x-irradiated mammalian cells. , 1976, Proceedings of the National Academy of Sciences of the United States of America.
[105] R. Mortimer,et al. A genetic study of x-ray sensitive mutants in yeast. , 1974, Mutation research.